Limit of detection: 80% B/B₀: 16 pg/ml · Sensitivity: 50% B/B₀: 110 pg/ml · Fluprostenol is a metabolically stable analog of PGF_2α with potent FP receptor agonist activity.^1,2 The isopropyl ester of fluprostenol has recently been approved for use as an ocular hypotensive drug for the treatment of glaucoma and is sold under the Alcon trade name Travoprost.^3,4 Acting as a prodrug, Fluprostenol isopropyl ester is converted by esterase activity in the cornea to yield the corresponding active free acid, (+)-fluprostenol.⁵ Fluprostenol is also used in the veterinary field for the induction of estrus in livestock. Cayman’s Fluprostenol EIA is a sensitive detection method for measuring the free acid form of fluprostenol. The assay also detects the isopropyl ester form of fluprostenol, but with less sensitivity. Samples containing a mixture of the isopropyl ester and free acid should be purified and the compounds separated prior to analysis. The assay has been validated for use in aqueous humor samples.

1 Abramovitz, M., Boie, Y., Nguyen, T., et al. Cloning and expression of a cDNA for the human prostanoid FP receptor. J Biol Chem 269 2632-2636 (1994).

2 Lake, S., Gullberg, H., Wahlqvist, J., et al. Cloning of the rat and human prostaglandin F_2α receptors and the expression of the rat prostaglandin F_2α receptor. FEBS Lett 355 317-325 (1994).

3 Sorbera, L.A., and Castañer, J. Travoprost. Drugs Future 25 41-45 (2000).

4 Hellberg, M.R., Sallee, V.L., Mclaughlin, M.A., et al. Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist. J Ocul Pharmacol Ther 17(5) 421-432 (2001).

5 Stjernschantz, J., and Resul, B. Phenyl substituted prostaglandin analogs for glaucoma treatment. Drugs Future 17 691-704 (1992).

Dukes, M., Russell, W., and Walpole, A.L. Potent luteolytic agents related to prostaglandin F_2α. Nature 250 330-331 (1974).

Sorbera, L.A., and Castañer, J. Travoprost. Drugs Future 25 41-45 (2000).

Hellberg, M.R., Sallee, V.L., Mclaughlin, M.A., et al. Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist. J Ocul Pharmacol Ther 17(5) 421-432 (2001).

Abramovitz, M., Boie, Y., Nguyen, T., et al. Cloning and expression of a cDNA for the human prostanoid FP receptor. J Biol Chem 269 2632-2636 (1994).

Lake, S., Gullberg, H., Wahlqvist, J., et al. Cloning of the rat and human prostaglandin F_2α receptors and the expression of the rat prostaglandin F_2α receptor. FEBS Lett 355 317-325 (1994).

Stjernschantz, J., and Resul, B. Phenyl substituted prostaglandin analogs for glaucoma treatment. Drugs Future 17 691-704 (1992).

Binder, D., Bowler, J., Brown, E.D., et al. 16-Aryloxyprostaglandins: A new class of potent luteolytic agent. Prostaglandins 6 87-90 (1974).

Maxey, K.M., Maddipati, K.R., and Birkmeier, J. Interference in enzyme immunoassays. J Clin Immunoassay 15 116-120 (1992).

Pradelles, P., Grassi, J., and Maclouf, J.A. Enzyme immunoassays of eicosanoids using acetylcholinesterase as label: An alternative to radioimmunoassay. Anal Chem 57 1170-1173 (1985).

Maclouf, J., Grassi, J., and Pradelles, P. Development of enzyme-immunoassay techniques for the measurement of eicosanoids. 355-364 (1987).

McCue, B.A., Cason, M.M., Curtis, M.A., et al. Determination of travoprost and travoprost free acid in human plasma by electrospray HPLC/MS/MS. J Pharm Biomed Anal 28 199-208 (2002).

Show all 11 Hide all but first 3